Cita APA

Scrima, M., Zito Marino, F., Oliveira, D. M., Marinaro, C., La Mantia, E., Rocco, G., . . . Viglietto, G. (2017). Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients. J Cancer.

Chicago Style Citation

Scrima, Marianna, et al. "Aberrant Signaling Through the HER2-ERK1/2 Pathway Is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients." J Cancer 2017.

Cita MLA

Scrima, Marianna, et al. "Aberrant Signaling Through the HER2-ERK1/2 Pathway Is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients." J Cancer 2017.